drug

Guanfacine

MeSH D016316
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Icahn School of Medicine at Mount Sinai
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
CRT-Guanfacine for SPD
NCT02524899Phase 2Completed
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects
NCT01600885—Completed

KOLs & investigators

3
Margaret McNamara McClure, Ph.D.KOL score 5
John W. Newcomer, M.D.KOL score 5
Naomi R Driesen, Ph.D.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Icahn School of Medicine at Mount Sinai
company
trial
CRT-Guanfacine for SPD
PHASE2
trial
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects
NA
trial
indication
Schizophrenia
indication
NMDA Receptor Function
indication
Schizotypal Personality Disorder
indication
Cognitive Dysfunction
indication
KOL
Margaret McNamara McClure, Ph.D.
KOL score 5
person
John W. Newcomer, M.D.
KOL score 5
person
Naomi R Driesen, Ph.D.
KOL score —
person